IBB – Challenging 2016, Recovering 2017 And Resurgence In 2018

Introduction:
The Biotechnology cohort has finally broken out and reached a 52-week high while making up much of the lost ground during the pummeling from both sides of the political isle during the 2016 presidential race. Tweets and excerpts during the campaign trail from Hillary Clinton, Bernie Sanders and Donald Trump put the biotech cohort through the wringer via taking aim at drug pricing. The sustained sell-off lead to the entire cohort to sell off from all-time highs of $132 to $83 or 37% in only 6 months as measured via the iShares Nasdaq Biotechnology ETF (IBB). From February of 2016 through June of 2017 IBB traded in a tight range from $83 to $98 while Donald Trump continually fired shots against the healthcare sector. Any healthcare related stocks became volatile on the heels of any statement or tweet from Donald Trump.

Shortly after inauguration, Trump stated that drug companies are “getting away with murder” when speaking to the drug pricing issue. The previously proposed healthcare legislation never materialized thus a level of certainty has entered the picture and the drug pricing threats are not perceived to be as bad as initially feared. Recently the index has had a resurgence moving to a 52-week high of $118 with a much clearer runway ahead as the political headwinds continue to abate. As the confluence of abating political threats, drug pricing certainty, merger and acquisition activity ramps and continuity of the current healthcare backdrop, I feel the index has room to continue its upward trend and retrace its 2015 level of $130.  


AbbVie Earnings Setting the Tone:
AbbVie (ABBV) reported Q4 numbers that beat expectations and updated guidance above consensus estimates for 2018 and as result the stock moved up 14%. This earnings announcement stroked the entire biotech cohort and has pumped more life into the group that has seen a steady rise leading up to this announcement. Other large-cap companies that have plenty of upside based on its multi-year highs include Celgene (CELG) which is off 35%, Regeneron (REGN) which is off 31% and Gilead (GILD) which is off 29% based on current prices. Even specialty pharma Allergan (AGN) is off a staggering 43% as well. All of these names may be due for a resurgence if quarterly results beat and guidance is raised in similar fashion as AbbVie.    

1 2 3 4
View single page >> |

Disclosure: The author does not currently hold shares of IBB however the author owns shares of Allergan, Celgene, Gilead and Regeneron. The author has no business relationship with any companies ...

more
How did you like this article? Let us know so we can better customize your reading experience. Users' ratings are only visible to themselves.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.
Duanne Johnson 1 year ago Member's comment

Impressive stuff.

Noah Kiedrowski 1 year ago Author's comment

Thanks for reading, hopefully 2018 will be a better year for this cohort.

Dean Gilmore 1 year ago Member's comment

Excellent read.

Noah Kiedrowski 1 year ago Author's comment

Thanks Dean! Appreciate the positive feedback.